Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02011945 · ClinicalTrials.gov registry record · Phase 1
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02011945 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants.
The verdict
NCT02011945, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Interventions
- DRUG Nivolumab
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-02-07 |
| Est. Completion | 2018-12-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02011945
The ClinicalTrials.gov registry entry for NCT02011945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02011945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02011945 about?
NCT02011945 is a clinical study titled "A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia". The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
What is the current status of trial NCT02011945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2014-02-07. Estimated completion is 2018-12-26.
What interventions are being tested in trial NCT02011945?
The interventions under investigation include: Nivolumab (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT02011945?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.